Innovation & Leadership in Engineering Technologies and Therapies for Diabetes

创新

• 批准号: 8545172
• 负责人: JULIA E BABENSEE
• 金额: $ 15.82万
• 依托单位: GEORGIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-17 至 2015-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8545172
• 关键词: Academia; Affect; Area; Artificial Pancreas; Autologous; Beta Cell; Biocompatible Materials; Biological; Biomedical Engineering; Biotechnology; Caring; Cell Therapy; Cells; Clinical; Complex; Development; Diabetes Mellitus; Economic Burden; Encapsulated; Engineering; Engraftment; Exposure to; Generations; Glucose; Health; Health Care Costs; Hydrogels; Immune; Industry; Injection of therapeutic agent; Institutes; Insulin; Insulin Infusion Systems; Insulin-Dependent Diabetes Mellitus; Joints; Leadership; Life; Methods; Microfabrication; Pancreas; Patient Care; Patients; Physiological; Population; Positioning Attribute; Process; Protocols documentation; Quality of life; Research; Research Training; Sampling; Science; System; Technology; Tissues; Training; Training Programs; Transplantation; Universities; base; beta cell replacement; blood glucose regulation; commercialization; diabetes management; diabetes mellitus therapy; diabetic; improved; innovation; islet; islet allograft; islet xenograft; medical schools; next generation; non-invasive monitor; novel; post-doctoral training; programs; translational medicine

DESCRIPTION (provided by applicant): The Diabetes Program: Innovation & Leadership in Engineering Technologies and Therapies (ILET2) is a unique, cross-disciplinary postdoctoral training program in cell- and tissue-based therapies and novel insulin delivery technologies for insulin-dependent diabetes (IDD). IDD is a significant health problem affecting millions of people in the U.S and worldwide. Compared to current treatments based on insulin injections or open-loop insulin pumps, new generation therapies have the potential to provide a less invasive, more physiologic and ultimately less costly regulation of blood glucose levels, potentially reducing long-term complications and revolutionizing diabetes care. There is a critical need for cross-disciplinary training of bioengineers and bioscientists in the complex problems relating to developing living biological substitutes for beta cell replacement and the artificial pancreas, which encompass fundamental science, bioengineering and translational medicine. ILET2 is a joint training program between the Georgia Institute of Technology and Emory University School of Medicine. This program will train the future research experts in this field by providing trainee with expertise in the following areas critical to advancing the next generation therapies for diabetes: 1) the ability to develop new islet encapsulation and engraftment systems, including new biomaterials and processes; 2) the ability to engineer immune acceptance of islet allografts and xenografts; 3) the ability to engineer non-beta insulin- secreting, physiologically responsive cells as an alternative to islets; and 4) the ability to develop new methods for glucose sampling and insulin delivery towards a closed loop artificial pancreas system. Research-based training in cell-based therapies will specialize in encapsulated systems for islets and other insulin-secreting cells; the engineering of potentially autologous beta cell surrogates; the development of vasculogenic hydrogels for improved islet engraftment; methods to conduct non-invasive monitoring of islet transplants; and development of immune acceptance protocols for free and encapsulated islet allografts and xenografts. Training specific to insulin delivery methods will focus on the engineering of microneedle technologies for glucose sampling and delivery of insulin, including microfabrication and biomaterials, ultimately as part of a closed loop artificia pancreas system. The research training program will encompass exposure to the clinical aspects of diabetes management and patient care, as well as the industrial aspects of biotechnology development and commercialization. Upon successful completion of the program, trainees will be prepared to move into leadership positions in industry and academia and develop new, cutting-edge technologies and therapies for diabetics aimed at improving the quality of life of patients and reducing the economic burden on the diabetic population and the overall healthcare costs.

糖尿病项目：工程技术和治疗的创新与领导力（ILET 2）是一个独特的，跨学科的博士后培训计划，以细胞和组织为基础的治疗和胰岛素依赖型糖尿病（IDD）的新型胰岛素输送技术。IDD是影响美国和全世界数百万人的重大健康问题。与目前基于胰岛素注射或开环胰岛素泵的治疗方法相比，新一代疗法有可能提供侵入性更小、更符合生理学、最终成本更低的血糖水平调节，从而有可能减少长期并发症并彻底改变糖尿病护理。迫切需要对生物工程师和生物科学家进行跨学科培训，以解决与开发β细胞替代品和人工胰腺有关的复杂问题，其中包括基础科学、生物工程和转化医学。 ILET 2是格鲁吉亚理工学院和埃默里大学医学院之间的联合培训计划。该计划将通过为学员提供以下领域的专业知识来培养该领域的未来研究专家，这些领域对推进下一代糖尿病治疗至关重要：1）开发新的胰岛封装和植入系统的能力，包括新的生物材料和工艺; 2）设计胰岛同种异体移植物和异种移植物的免疫接受能力; 3）工程化非β胰岛素分泌的生理响应细胞作为胰岛的替代物的能力;和4）开发用于葡萄糖采样和胰岛素递送的新方法朝向闭环人工胰腺系统的能力。基于细胞疗法的研究培训将专注于胰岛和其他胰岛素分泌系统的封装。 细胞;潜在自体β细胞替代物的工程化;用于改善胰岛移植的血管生成水凝胶的开发;进行胰岛移植的非侵入性监测的方法;以及游离和包封的胰岛同种异体移植物和异种移植物的免疫接受方案的开发。针对胰岛素输送方法的培训将侧重于葡萄糖采样和胰岛素输送的微针技术工程，包括微加工和生物材料，最终作为闭环人工胰腺系统的一部分。 研究培训计划将包括接触糖尿病管理和患者护理的临床方面，以及生物技术开发和商业化的工业方面。成功完成该计划后，学员将准备进入工业界和学术界的领导岗位，并为糖尿病患者开发新的尖端技术和疗法，旨在改善患者的生活质量，减轻糖尿病患者的经济负担和整体医疗费用。